Effect of erythromycin on mortality and the host response in critically ill patients with sepsis: a target trial emulation.

ABSTRACT:

Background

Immunomodulatory therapies that improve the outcome of sepsis are not available. We sought to determine whether treatment of critically ill patients with sepsis with low-dose erythromycin-a macrolide antibiotic with broad immunomodulatory effects-decreased mortality and ameliorated underlying disease pathophysiology.

Methods

We conducted a target trial emulation, comparing patients with sepsis admitted to two intensive care units (ICU) in the Netherlands for at least 72 h, who were either exposed or not exposed during this period to treatment with low-dose erythromycin (up to 600 mg per day, administered as a prokinetic agent) but no other macrolides. We used two common propensity score methods (matching and inverse probability of treatment weighting) to deal with

SUBMITTER: Reijnders TDY 

PROVIDER: S-EPMC9128233 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature